Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About Molecular Pharmacology
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About Molecular Pharmacology
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells

Un-Ho Jin, Yating Cheng, Beiyan Zhou and Stephen Safe
Molecular Pharmacology May 2017, 91 (5) 438-450; DOI: https://doi.org/10.1124/mol.116.106245
Un-Ho Jin
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yating Cheng
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beiyan Zhou
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Safe
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Modulation of thiols by Bar-Me, CDODA-Me, and CF3DODA-Me in leukemia cells. (A) Structures of oleanolic and glycyrrhetinic acid–derived triterpenoids CDDO-Me (Bar-Me), CDODA-Me, and CF3DODA-Me. (B) Spectral changes in Bar-Me, CDODA-Me, and CF3DODA-Me after incubation with GSH. (C) Comparative A-, B-, and C-ring structures of Bar-Me and CDODA-Me/CF3DODA-Me. (D) Cells were treated with dimethylsulfoxide (DMSO), Bar-Me, and CF3DODA-Me for 6 hours, and TNFα was then added for 15 minutes. Whole cell lysates were analyzed by western blots as outlined in Materials and Methods.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Bar-Me and CF3DODA-Me inhibit leukemia cell growth and induce apoptosis and differentiation of leukemia cells. HL-60 and Jurkat cells were treated with Bar-Me (A) or CF3DODA-Me (B) and growth inhibition was determined using the XTT assay. HL-60 and Jurkat cells were treated with Bar-Me or CF3DODA-Me for 24 hours and the effects of cleaved PARP and caspases (C), annexin V staining (D), and apoptosis were determined by western blots and FACS analysis for annexin V and propidium iodide staining, respectively, as outlined in Materials and Methods. Cells were treated with dimethylsulfoxide (DMSO), Bar-Me, and CF3DODA-Me for 72 hours and differentiation markers (CD11b) (E) in HL-60 and CD4 in Jurkat (F) cells were determined by FACS analysis as outlined in Materials and Methods. Results are expressed as mean ± S.E.M. for at least three replicate determinations and significant (P < 0.05) changes (compared with DMSO) are indicated (#).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Bar-Me and CF3DODA-Me induce ROS in leukemia cells. HL-60 (A) and Jurkat (B) cells were pretreated with GSH for 1 hour, and then treated with dimethylsulfoxide (DMSO), Bar-Me, or CF3DODA-Me for 3 hours. ROS was determined by FACS analysis as outlined in Materials and Methods. (C) Cells were treated with DMSO, Bar-Me, or CF3DODA-Me alone or in combination with GSH for 24 hours and cell proliferation was determined using the XTT assay as outlined in Materials and Methods. (D) Cells were treated with DMSO, Bar-Me, or CF3DODA-Me alone or in combination with GSH for 24 hours, and cleaved PARP and caspases were determined by western blots of whole cell lysates as outlined in Materials and Methods. Results are expressed as mean ± S.E.M. for at least three replicate determinations and significant (P < 0.05) effects of the compounds (#) and reversal of specific effects by GSH (*) are indicated.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Bar-Me and CF3DODA-Me induce markers of differentiation and maturation. HL-60 cells were treated with Bar-Me or CF3DODA-Me alone or in combination with GSH and the effects of CD11b mRNA (A) and protein levels (B) were determined after 24 and 72 hours, respectively, as outlined in Materials and Methods. Jurkat cells were treated with Bar-Me or CF3DODA-Me alone or in combination with GSH and CD4 (C) and were determined by FACS analysis after 72 hours and IL-2, IL-4, and IL-13 mRNA after 24-hour levels (D) were determined by real-time PCR as outlined in Materials and Methods. Results are expressed as mean ± S.E.M. (at least three replicate determinations), and significant (P < 0.05) induction by the compound (#) and inhibition by GSH (*) are indicated.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Bar-Me and CF3DODA-Me decrease Sp proteins and cMyc in leukemia cells. (A) Cells were treated with dimethylsulfoxide (DMSO), Bar-Me, or CF3DODA-Me for 24 hours and whole cell lysates were analyzed by western blots as outlined in Materials and Methods. (B) Cells were treated with DMSO, Bar-Me, or CF3DODA-Me alone or in combination with GSH for 24 hours and whole cell lysates were analyzed by western blots as outlined in Materials and Methods. (C) Cells were treated with DMSO, Bar-Me, or CF3DODA-Me for 3, 6, or 12 hours and whole cell lysates were analyzed by western blots as outlined in Materials and Methods. (D) Cells were treated with DMSO, Bar-Me, or CF3DODA-Me alone or in combination with GSH for 9 hours and analyzed by western blots as outlined in Materials and Methods, and results are expressed as mean ± S.E.M. for at least three replicate determinations. Significant (P < 0.05) effects of the compounds (#) and reversal by GSH (*) are indicated.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Role of cMyc and Sp TFs in leukemia cell growth, differentiation, and maturation. Knockdown of Sp1 (siSp1), Sp3 (siSp3), Sp4 (siSp4), all three Sp TFs (siSp1/3/4), and cMyc (sicMyc) in HL-60 cells was carried out by RNA interference, and the effects on protein expression (A) and cell proliferation (B) were determined by western blots and the XTT assay. Effects of knockdown on CD11b mRNA and cellular expression of CD11b protein (C) were determined by real-time PCR and FACS analysis, respectively. Jurkat cells were transfected with siSp1, siSp3, siSp4, siSp1/3/4, and sicMyc, and effects on protein levels (D), cell growth (E), CD4-positive cells (F), and IL-2, IL-4, and IL-3 mRNA levels (G) were determined by western blots, XTT assay, FACS analysis, and real-time PCR, respectively, as outlined in Materials and Methods. Results are expressed as mean ± S.E.M. (three replicate determinations) and significant (P < 0.05) effects compared with dimethylsulfoxide control are indicated (#).

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Inactivation of mTOR and Akt by Bar-Me and CF3DODA-Me. (A) Cells were treated with Bar-Me or CF3DODA-Me alone or in combination with 5 mM GSH for 12 hours and analyzed by western blots. Cells were treated with LY294002 (PI3K) and MK2208 (Akt) kinase inhibitors for 24 hours, and whole cell lysates were analyzed by western blots (B) by determining the effects on cell growth in HL-60 and Jurkat cells (C) and on CD11b (HL-60 cells) (D) and CD4 (Jurkat cells) (E) differentiation markers as outlined in Materials and Methods. Results (C–E) are mean ± S.E.M. for at least three replicate determinations and significant (P < 0.05) differences compared with dimethylsulfoxide (DMSO) (control) are indicated (#).

Additional Files

  • Figures
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Figures -

      Supplemental Figure 1 - GSH inhibits Bar-Me- and CF3DODA-Meinduced apoptosis

      Supplemental Figure 2 - Bar-Me and CF3DODA-Me decrease mitochondrial membrane potential and Sp proteins in leukemia cells

      Supplementary Figure 3 - Effects of Tiron. HL-60 and Jurkat cells were treated with DMSO, Bar-Me, or CF3DODA-Me alone or in combination with 100 mu-M Tiron for 24 hrs and effects on induction of ROS in HL60 (A) and Jurkat (B) cells and cell growth inhibition (C) were determined

      Supplementary Figure 4 - Effects of Tiron. HL-60 and Jurkat cells were treated with DMSO, Bar-Me, or CF3DODA-Me alone or in combination with 100 mu-M Tiron for 72 hr (FACS analysis) or 9 hr (Western blot) and effects on CD11b (A), CD4 (B), and protein levels (C) were determined

      Supplemental Figure 5 - Bar-Me and CF3DODA-Me do not induce ZBTB proteins

      Supplemental Figure 6 - HL-60 and Jurkat cells were treated with DMSO (control), 0.5 mu-M Bar- Me, and 2 mu-M CF3DODA-Me for 3, 6 or 12 hr

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 91 (5)
Molecular Pharmacology
Vol. 91, Issue 5
1 May 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Research ArticleArticle

Triterpenoids Induce ROS-Dependent cMyc Downregulation

Un-Ho Jin, Yating Cheng, Beiyan Zhou and Stephen Safe
Molecular Pharmacology May 1, 2017, 91 (5) 438-450; DOI: https://doi.org/10.1124/mol.116.106245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Triterpenoids Induce ROS-Dependent cMyc Downregulation

Un-Ho Jin, Yating Cheng, Beiyan Zhou and Stephen Safe
Molecular Pharmacology May 1, 2017, 91 (5) 438-450; DOI: https://doi.org/10.1124/mol.116.106245
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes
  • Assessment of the molecular mechanisms of action of novel 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one allosteric modulators at the M1 muscarinic acetylcholine receptors.
  • A Transcriptional Regulatory Network Containing Nuclear Receptors and lncRNAs Controls Basal and Drug-Induced Expression of Cytochrome P450s in HepaRG Cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2018 by the American Society for Pharmacology and Experimental Therapeutics